Recent randomized controlled trials demonstrate that open-label placebos can improve outcomes, like pain management and reduced opioid use, even when patients know they are receiving a placebo. These findings shift the conversation about placebos from whether deception is ethical to what role they should play in health care. Panel discussion organized by the Center for Bioethics at Harvard Medical School; Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics; and the Program on Regulation, Therapeutics, and Law (PORTAL).
This NIH Collaboratory Rethinking Clinical Trials Grand Rounds features:
Corita R. Grudzen, MD, MSHS, FACEP
Fern Grayer Chair in Oncology Care and the Patient Experience
Division Head, Supportive and Acute Care Services
Memorial Sloan Kettering Cancer Center
Professor of Emergency Medicine
Weill Cornell Medical College